Skip to main content
Top
Published in: Cancer Chemotherapy and Pharmacology 4/2005

01-10-2005 | Original Article

Identification of biliary metabolites of ifosfamide using 31P magnetic resonance spectroscopy and mass spectrometry

Authors: Geoffrey S Payne, Andrzej SK Dzik-Jurasz, Laura Mancini, Bernard Nutley, Florence Raynaud, Martin O Leach

Published in: Cancer Chemotherapy and Pharmacology | Issue 4/2005

Login to get access

Abstract

Biliary excretion is a significant component in the metabolism of many drugs, but remains difficult to detect and characterise non-invasively. A previous publication recently described the detection of metabolites of ifosfamide in gall bladder in a guinea pig model using in vivo 1H-decoupled 31P 3-D magnetic resonance spectroscopic imaging and a clinical 1.5 T MR scanner.. Here high-resolution 31P magnetic resonance spectroscopy (MRS) of extracted bile identifies peaks as parent ifosfamide (1.19±1.47 mM; mean ± sd), carboxyifosfamide (2.04±1.04 mM) and a major contribution from a previously unreported peak at 16.0 ppm (4.05±2.38 mM). The unknown resonance was identified using liquid chromatography - mass spectrometry (LCMS) as the glutathione conjugate of ifosfamide (MW = 531). This was confirmed by analysing products from the reaction of glutathione with ifosfamide using LCMS and MRS. These results demonstrate how combined in vivo and analytical MRS, together with mass spectrometry, can help identify visceral routes of drug metabolism, thereby aiding understanding of ±drug disposition and mechanisms of action and toxicity. In particular, the distribution of ifosfamide and its metabolites into bile may be related to oxazophosphorine-related cholecystitis reported in patients.
Literature
1.
go back to reference Klaassen CD, Watkins JB (1984) 3rd Mechanisms of bile formation, hepatic uptake, and biliary excretion. Pharmacol Rev 36:1–67PubMed Klaassen CD, Watkins JB (1984) 3rd Mechanisms of bile formation, hepatic uptake, and biliary excretion. Pharmacol Rev 36:1–67PubMed
2.
go back to reference Sigers CP, Watkins III JB (eds) (1991) Biliary excretion of drugs and other chemicals, 1st edn. Gustav Fischer Verlag, New York Sigers CP, Watkins III JB (eds) (1991) Biliary excretion of drugs and other chemicals, 1st edn. Gustav Fischer Verlag, New York
3.
go back to reference Karachalios G, Charalabopoulos K (2002) Biliary excretion of antimicrobial drugs, Vol 48, pp 280–297 Karachalios G, Charalabopoulos K (2002) Biliary excretion of antimicrobial drugs, Vol 48, pp 280–297
4.
go back to reference Klaassen CD (2002) Xenobiotic transporters: another protective mechanism for chemicals. Int J Toxicol 21:7–12CrossRefPubMed Klaassen CD (2002) Xenobiotic transporters: another protective mechanism for chemicals. Int J Toxicol 21:7–12CrossRefPubMed
5.
go back to reference Clarke SJ, Rivory LP (1999) Clinical pharmacokinetics of docetaxel. Clin Pharmacokinet 36:99–114PubMed Clarke SJ, Rivory LP (1999) Clinical pharmacokinetics of docetaxel. Clin Pharmacokinet 36:99–114PubMed
6.
go back to reference Scripture CD, Pieper JA (2001) Clinical pharmacokinetics of fluvastatin. Clin Pharmacokinet, pp 263–281 Scripture CD, Pieper JA (2001) Clinical pharmacokinetics of fluvastatin. Clin Pharmacokinet, pp 263–281
7.
go back to reference Geubel AP, Sempoux CL (2000) Drug and toxin-induced bile duct disorders. J Gastroenterol Hepatol 15:1232–1238CrossRefPubMed Geubel AP, Sempoux CL (2000) Drug and toxin-induced bile duct disorders. J Gastroenterol Hepatol 15:1232–1238CrossRefPubMed
8.
go back to reference Rossi AN, Rossi MB (1983) Meltzer-Lyon test simultaneous with fiberoptic gastroduodenoscopy. Surg Gynecol Obstet 157:378–379PubMed Rossi AN, Rossi MB (1983) Meltzer-Lyon test simultaneous with fiberoptic gastroduodenoscopy. Surg Gynecol Obstet 157:378–379PubMed
9.
go back to reference Mancini L, Payne GS, Dzik-Jurasz AS, Leach MO (2003) Ifosfamide pharmacokinetics and hepatobiliary uptake in vivo investigated using single- and double-resonance 31P MRS. Magn Reson Med 50:249–255CrossRefPubMed Mancini L, Payne GS, Dzik-Jurasz AS, Leach MO (2003) Ifosfamide pharmacokinetics and hepatobiliary uptake in vivo investigated using single- and double-resonance 31P MRS. Magn Reson Med 50:249–255CrossRefPubMed
10.
go back to reference Fleming RA (1997) An overview of cyclophosphamide and ifosfamide pharmacology. Pharmacotherapy 17:146S–154SPubMed Fleming RA (1997) An overview of cyclophosphamide and ifosfamide pharmacology. Pharmacotherapy 17:146S–154SPubMed
11.
go back to reference Martino R, Crasnier F, Chouini-Lalanne N, Gilard V, Niemeyer U, De Forni M, Malet-Martino M-C (1992) A new approach to the study of ifosfamide metabolism by the analysis of human body fluids with 31P nuclear magnetic resonance spectroscopy. J Pharmacol Experiment Therapeut 260:1133–1144 Martino R, Crasnier F, Chouini-Lalanne N, Gilard V, Niemeyer U, De Forni M, Malet-Martino M-C (1992) A new approach to the study of ifosfamide metabolism by the analysis of human body fluids with 31P nuclear magnetic resonance spectroscopy. J Pharmacol Experiment Therapeut 260:1133–1144
12.
go back to reference Gibson G, Skett P (2001) Introduction to Drug Metabolism, 3rd edn. Nelson Thorns Gibson G, Skett P (2001) Introduction to Drug Metabolism, 3rd edn. Nelson Thorns
13.
go back to reference Prescot AP, Collins DJ, Leach MO, Dzik-Jurasz AS (2003) Human gallbladder bile: noninvasive investigation in vivo with single-voxel 1H MR spectroscopy. Radiology 229:587–592PubMed Prescot AP, Collins DJ, Leach MO, Dzik-Jurasz AS (2003) Human gallbladder bile: noninvasive investigation in vivo with single-voxel 1H MR spectroscopy. Radiology 229:587–592PubMed
14.
go back to reference Dzik-Jurasz AS, Collins DJ, Leach MO, Rowland IJ (2000) Gallbladder localization of (19)F MRS catabolite signals in patients receiving bolus and protracted venous infusional 5-fluorouracil. Magn Reson Med 44:516–520CrossRefPubMed Dzik-Jurasz AS, Collins DJ, Leach MO, Rowland IJ (2000) Gallbladder localization of (19)F MRS catabolite signals in patients receiving bolus and protracted venous infusional 5-fluorouracil. Magn Reson Med 44:516–520CrossRefPubMed
15.
go back to reference Ransohoff DF, Gracie WA (1993) Treatment of Gallstones. Ann Intern Med 119:606-619PubMed Ransohoff DF, Gracie WA (1993) Treatment of Gallstones. Ann Intern Med 119:606-619PubMed
16.
go back to reference Kalliafas S, Ziegler DW, Flancbaum L, Choban PS (1998) Acute acalculous cholecystitis: incidence, risk factors, diagnosis, and outcome. Am Surg 64:471–475PubMed Kalliafas S, Ziegler DW, Flancbaum L, Choban PS (1998) Acute acalculous cholecystitis: incidence, risk factors, diagnosis, and outcome. Am Surg 64:471–475PubMed
17.
go back to reference Michielsen PP, Fierens H, Van Maercke YM (eds) (1992) Drug-induced gallbladder disease. Incidence, aetiol Manage 7:32–45 Michielsen PP, Fierens H, Van Maercke YM (eds) (1992) Drug-induced gallbladder disease. Incidence, aetiol Manage 7:32–45
18.
go back to reference Adusumilli PS, Lee B, Parekh K, Farrelly PA (2002) Acalculous eosinophilic cholecystitis from herbal medicine: a review of adverse effects of herbal medicine in surgical patients. Surgery 131:352–356CrossRefPubMed Adusumilli PS, Lee B, Parekh K, Farrelly PA (2002) Acalculous eosinophilic cholecystitis from herbal medicine: a review of adverse effects of herbal medicine in surgical patients. Surgery 131:352–356CrossRefPubMed
19.
go back to reference Famularo G, Polchi S, De Simone C (1999) Acute cholecystitis and pancreatitis in a patient with biliary sludge associated with the use of ceftriaxone: a rare but potentially severe complication. Ann Ital Med Int 14:202–204PubMed Famularo G, Polchi S, De Simone C (1999) Acute cholecystitis and pancreatitis in a patient with biliary sludge associated with the use of ceftriaxone: a rare but potentially severe complication. Ann Ital Med Int 14:202–204PubMed
Metadata
Title
Identification of biliary metabolites of ifosfamide using 31P magnetic resonance spectroscopy and mass spectrometry
Authors
Geoffrey S Payne
Andrzej SK Dzik-Jurasz
Laura Mancini
Bernard Nutley
Florence Raynaud
Martin O Leach
Publication date
01-10-2005
Publisher
Springer-Verlag
Published in
Cancer Chemotherapy and Pharmacology / Issue 4/2005
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI
https://doi.org/10.1007/s00280-005-1023-2

Other articles of this Issue 4/2005

Cancer Chemotherapy and Pharmacology 4/2005 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine